Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2714092 | 0.91 | MAPT (0.61) | NCF1MAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL1248587 | 0.74 | MAPT (0.58) | NCF1MAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL38657246 | 0.73 | KDM4C (0.40) | MAPTKDM4EPARP1 | |
| Quinoxaline SCHEMBL29355228 | 0.73 | ALDH1A1 (0.58) | NCF1MAPTKDM4ELOXL2HTR1A | |
| Quinoxaline SCHEMBL30320908 | 0.73 | ALDH1A1 (0.58) | NCF1MAPTKDM4ELOXL2HTR1A | |
| Quinoxaline SCHEMBL6928518 | 0.73 | ALDH1A1 (0.58) | NCF1MAPTKDM4ELOXL2HTR1A | |
| Quinoxaline SCHEMBL5315 | 0.73 | ALDH1A1 (0.58) | NCF1MAPTKDM4ELOXL2HTR1A | |
| SCHEMBL8127895 | 0.71 | NCF1 (0.50) | NCF1MAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2877514 | 0.71 | CYP3A4 (0.54) | NCF1MAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL128548 | 0.71 | NCF1 (0.56) | NCF1MAPTKDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979658-B | Preparation method of flumazenil | 南湖实验室 | 2022-05-31 | — | — | CN | claimed |
| US-8063204-B2 | Benzothiazole and benzoxazole linked pyrrolo[2,1-c] [1, 4] benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-11-22 | — | — | US | claimed |
| EP-2350085-A1 | QUINAZOLINONE LINKED PYRROLOÝ2,1 -C¨Ý1.4¨BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF | Council Of Scientific & Industrial Research (IN) | 2011-08-03 | — | — | EP | claimed |
| WO-2010058416-A1 | QUINAZOLINONE LINKED PYRROLO[2,1 -C][1.4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-05-27 | — | — | WO | claimed |
| EP-2061795-A2 | PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND A PROCESS FOR THE PREPARATION THEREOF | Council Of Scientific&industrial Research (IN) | 2009-05-27 | — | — | EP | claimed |
| WO-2008020455-A2 | PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020456-A2 | PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-02-21 | — | — | WO | claimed |
| WO-2007054954-A1 | A NOVEL PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRID AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2007-05-18 | — | — | WO | claimed |
| WO-2005089515-A9 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-0987266-A1 | BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2000-03-22 | — | — | EP | claimed |
| US-5962337-A | ATTACHING AMINO-PROTECTED ALPHA AMINOACID WHICH MAY BE N-ALKYLATED TO SOLID SUPPORT VIA CARBOXYL GROUP, CLEAVING AMINO PROTECTING GROUP, ACYLATING WITH 2-AZIDOBENZOYL CHLORIDE, CYCLIZING VIA AZA-WITTIG RING CLOSURE | PHARMACOPEIA, INC. (US) | 1999-10-05 | — | — | US | claimed |
| EP-0850238-A4 | COMBINATORIAL 1,4-BENZODIAZEPIN-2,5-DIONE LIBRARY | PHARMACOPEIA INC (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850238-A1 | COMBINATORIAL 1,4-BENZODIAZEPIN-2,5-DIONE LIBRARY | PHARMACOPEIA, INC. (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997001560-A1 | COMBINATORIAL 1,4-BENZODIAZEPIN-2,5-DIONE LIBRARY | PHARMACOPEIA, INC. (US) | 1997-01-16 | — | — | WO | claimed |
| EP-0393604-A2 | 6,11-Dihydro-5H-pyrido(2,3-b)(1,5,)benzodiazepin-5-ones and thiones and their use in the prevention or treatment of AIDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1990-10-24 | — | — | EP | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | disclosed |
| US-20250216392-A1 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | SANOFI-AVENTIS (FR) | 2025-07-03 | — | — | US | disclosed |
| WO-1981000568-A1 | BENZODIAZEPINONES,A PROCESS FOR THEIR PREPARATION,THEIR USE AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1981-03-05 | — | — | WO | disclosed |
| US-4111934-A | MUSCLE RELAXANT, ANTICONVULSANT, SEDATIVE | HOFFMANN-LA ROCHE INC. (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250216392-A1 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | CD38, MCL1, CD2 | NCF1 951/4885MAPT 4515/4885KDM4E 894/4885 |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | PRMT5, PRMT1, PRMT6 | NCF1 1076/4885MAPT 4880/4885KDM4E 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.